These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


163 related items for PubMed ID: 18479365

  • 1. When glycaemic targets can no longer be achieved with basal insulin in type 2 diabetes, can simple intensification with a modern premixed insulin help? Results from a subanalysis of the PRESENT study.
    Jang HC, Guler S, Shestakova M, PRESENT Study Group.
    Int J Clin Pract; 2008 Jul; 62(7):1013-8. PubMed ID: 18479365
    [Abstract] [Full Text] [Related]

  • 2. Addition of biphasic insulin aspart 30 to optimized metformin and pioglitazone treatment of type 2 diabetes mellitus: The ACTION Study (Achieving Control Through Insulin plus Oral ageNts).
    Raskin P, Matfin G, Schwartz SL, Chaykin L, Chu PL, Braceras R, Wynne A.
    Diabetes Obes Metab; 2009 Jan; 11(1):27-32. PubMed ID: 17941873
    [Abstract] [Full Text] [Related]

  • 3. Intensification to biphasic insulin aspart 30/70 (BIAsp 30, NovoMix 30) can improve glycaemic control in patients treated with basal insulins: a subgroup analysis of the IMPROVE observational study.
    Gumprecht J, Benroubi M, Borzi V, Kawamori R, Shaban J, Shah S, Shestakova M, Wenying Y, Ligthelm R, Valensi P, IMPROVE Study Group Expert Panel.
    Int J Clin Pract; 2009 Jun; 63(6):966-72. PubMed ID: 19504715
    [Abstract] [Full Text] [Related]

  • 4. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.
    Ushakova O, Sokolovskaya V, Morozova A, Valeeva F, Zanozina O, Sazonova O, Zhadanova E, Starceva M, Kazakova E, Saifullina M, Shapiro I, Tarasov A, Al-Tayar B, Starkova N.
    Clin Ther; 2007 Nov; 29(11):2374-84. PubMed ID: 18158078
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Efficacy of biphasic insulin aspart in patients with type 2 diabetes.
    Halimi S, Raskin P, Liebl A, Kawamori R, Fulcher G, Yan G.
    Clin Ther; 2005 Nov; 27 Suppl B():S57-74. PubMed ID: 16519038
    [Abstract] [Full Text] [Related]

  • 7. Safety and effectiveness of biphasic insulin aspart 30/70 (NovoMix 30) when switching from human premix insulin in patients with type 2 diabetes: subgroup analysis from the 6-month IMPROVE observational study.
    Shah S, Benroubi M, Borzi V, Gumprecht J, Kawamori R, Shaban J, Shestakova M, Wenying Y, Valensi P, IMPROVE Study Group Expert Panel.
    Int J Clin Pract; 2009 Apr; 63(4):574-82. PubMed ID: 19210701
    [Abstract] [Full Text] [Related]

  • 8. Self-titration of biphasic insulin aspart 30/70 improves glycaemic control and allows easy intensification in a Dutch clinical practice.
    Ligthelm RJ.
    Prim Care Diabetes; 2009 May; 3(2):97-102. PubMed ID: 19285933
    [Abstract] [Full Text] [Related]

  • 9. Does serum 1,5-anhydroglucitol establish a relationship between improvements in HbA1c and postprandial glucose excursions? Supportive evidence utilizing the differential effects between biphasic insulin aspart 30 and insulin glargine.
    Moses AC, Raskin P, Khutoryansky N.
    Diabet Med; 2008 Feb; 25(2):200-5. PubMed ID: 18290862
    [Abstract] [Full Text] [Related]

  • 10. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study).
    Garber AJ, Wahlen J, Wahl T, Bressler P, Braceras R, Allen E, Jain R.
    Diabetes Obes Metab; 2006 Jan; 8(1):58-66. PubMed ID: 16367883
    [Abstract] [Full Text] [Related]

  • 11. Predictors of achieving HbA(1c) <7% and no hypoglycaemia 6 months after initiation of biphasic insulin aspart 30 in patients with type 2 diabetes in the IMPROVE study.
    Valensi P, Shaban J, Benroubi M, Kawamori R, Borzì V, Shah S, Wenying Y, Prusty V, Hansen JB, Gumprecht J, IMPROVE Study Expert Panel.
    Curr Med Res Opin; 2013 Jun; 29(6):601-9. PubMed ID: 23488447
    [Abstract] [Full Text] [Related]

  • 12. Switching from human insulin to biphasic insulin aspart 30 treatment gets more patients with type 2 diabetes to reach target glycosylated hemoglobin < 7%: the results from the China cohort of the PRESENT study.
    Gao Y, Guo XH.
    Chin Med J (Engl); 2010 May 05; 123(9):1107-111. PubMed ID: 20529546
    [Abstract] [Full Text] [Related]

  • 13. Efficacy, safety and acceptability of biphasic insulin aspart 30 in Indian patients with type 2 diabetes: results from the PRESENT study.
    Sharma SK, Joshi SR, Kumar A, Unnikrishnan AG, Hoskote SS, Moharana AK, Chakkarwar PN, Vaz JA, PRESENT Study Group.
    J Assoc Physicians India; 2008 Nov 05; 56():859-63. PubMed ID: 19263683
    [Abstract] [Full Text] [Related]

  • 14. Biphasic insulin aspart 30 plus metformin: an effective combination in type 2 diabetes.
    Kvapil M, Swatko A, Hilberg C, Shestakova M.
    Diabetes Obes Metab; 2006 Jan 05; 8(1):39-48. PubMed ID: 16367881
    [Abstract] [Full Text] [Related]

  • 15. Three different premixed combinations of biphasic insulin aspart - comparison of the efficacy and safety in a randomized controlled clinical trial in subjects with type 2 diabetes.
    Cucinotta D, Smirnova O, Christiansen JS, Kanc K, le Devehat C, Wojciechowska M, López de la Torre M, Liebl A.
    Diabetes Obes Metab; 2009 Jul 05; 11(7):700-8. PubMed ID: 19476479
    [Abstract] [Full Text] [Related]

  • 16. Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial.
    Liebl A, Prager R, Binz K, Kaiser M, Bergenstal R, Gallwitz B, PREFER Study Group.
    Diabetes Obes Metab; 2009 Jan 05; 11(1):45-52. PubMed ID: 18643839
    [Abstract] [Full Text] [Related]

  • 17. A comparison of twice-daily biphasic insulin aspart 70/30 and once-daily insulin glargine in persons with type 2 diabetes mellitus inadequately controlled on basal insulin and oral therapy: a randomized, open-label study.
    Ligthelm RJ, Gylvin T, DeLuzio T, Raskin P.
    Endocr Pract; 2011 Jan 05; 17(1):41-50. PubMed ID: 20713345
    [Abstract] [Full Text] [Related]

  • 18. Risk for nocturnal hypoglycemia with biphasic insulin aspart 30 compared with biphasic human insulin 30 in adults with type 2 diabetes mellitus: a meta-analysis.
    Davidson JA, Liebl A, Christiansen JS, Fulcher G, Ligthelm RJ, Brown P, Gylvin T, Kawamori R.
    Clin Ther; 2009 Aug 05; 31(8):1641-51. PubMed ID: 19808125
    [Abstract] [Full Text] [Related]

  • 19. Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study.
    Wenying Y, Benroubi M, Borzi V, Gumprecht J, Kawamori R, Shaban J, Shah S, Shestakova M, Ligthelm R, Valensi P, IMPROVE Study Group Expert Panel.
    Curr Med Res Opin; 2009 Nov 05; 25(11):2643-54. PubMed ID: 19751116
    [Abstract] [Full Text] [Related]

  • 20. Biphasic insulin aspart 30 in the treatment of elderly patients with type 2 diabetes: a subgroup analysis of the PRESENT Korea NovoMixstudy.
    Jang HC, Lee SR, Vaz JA.
    Diabetes Obes Metab; 2009 Jan 05; 11(1):20-6. PubMed ID: 18479469
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 9.